clinical trial · NCT07293260
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
Amgen·phase3·recruiting·n = 406
Cardiovascular DiseaseOlpasiranPlacebo
brief summary
The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).
started
Mar 23, 2026
primary completion
Jun 15, 2028
completion
Jun 15, 2028
last updated
Apr 16, 2026
official title
A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol